This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schrevens, L. Articles by Vansteenkiste, J. Search for Related Content PubMed PubMed Citation Articles by Schrevens, L. Articles by Vansteenkiste, J.

The Role of PET Scan in Diagnosis, Staging, and Management of Non-Small Cell Lung Cancer

Respiratory Oncology Unit (Pulmonology) and Leuven Lung Cancer Group, University Hospital, Catholic University, Leuven, Belgium

Correspondence: Johan Vansteenkiste, M.D., Ph.D., Respiratory Oncology Unit (Pulmonology), University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. Telephone: 32-16-346800; Fax: 32-16-346803; e-mail: johan.vansteenkiste{at}uz.kuleuven.ac.be

Positron emission tomography (PET) is now an important cancer imaging tool, both for diagnosis and staging, as well as offering prognostic information based on response. This report attempts to comprehensively review the value of PET in the locoregional and distant staging of non-small cell lung cancer (NSCLC), illustrate the potential effects on patient management, and give a short overview of newer applications. PET sets the gold standard in the evaluation of an indeterminate solitary pulmonary nodule or mass, where PET has proven to be significantly more accurate than computed tomography (CT) in the distinction between benign and malignant lesions. In the evaluation of metastatic spread to locoregional lymph nodes, PET is significantly more accurate than CT, so that invasive surgical staging may be omitted in many patients with negative mediastinal PET images. In patients with positive mediastinal PET mages, invasive surgical staging remains mandatory because of the possibility of false-positive findings due to inflammatory nodes or granulomatous disorders. In the search for metastatic spread, PET is a useful adjunct to conventional imaging. This may be due to the finding of unexpected metastatic lesions or due to exclusion of malignancy in lesions that are equivocal on standard imaging. However, at this time, PET does not replace conventional imaging. Large-scale randomized studies are currently examining whether PET staging will actually improve the appearance of lung cancer outcome.

Key Words. FDG • Tomography • Emission computed • Lung neoplasms • Staging • Carcinoma • Non-small cell lung cancer

This article has been cited by other articles:

				S. Kligerman and S. Digumarthy Staging of Non-Small Cell Lung Cancer Using Integrated PET/CT Am. J. Roentgenol., November 1, 2009; 193(5): 1203 - 1211. [Full Text] [PDF]

				W. De Wever, S. Stroobants, J. Coolen, and J. A. Verschakelen Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration Eur. Respir. J., January 1, 2009; 33(1): 201 - 212. [Abstract] [Full Text] [PDF]

				D. Uesaka, Y. Demura, T. Ishizaki, S. Ameshima, I. Miyamori, M. Sasaki, Y. Fujibayashi, and H. Okazawa Evaluation of Dual-Time-Point 18F-FDG PET for Staging in Patients with Lung Cancer J. Nucl. Med., October 1, 2008; 49(10): 1606 - 1612. [Abstract] [Full Text] [PDF]

				S. A O'Keeffe, A. McGrath, and G. Wilson An interesting chest radiograph BMJ, September 24, 2008; 337(sep24_2): a1505 - a1505. [Full Text]

				B. D. Kozower, B. F. Meyers, C. E. Reed, D. R. Jones, P. A. Decker, and J. B. Putnam Jr Does Positron Emission Tomography Prevent Nontherapeutic Pulmonary Resections for Clinical Stage IA Lung Cancer? Ann. Thorac. Surg., April 1, 2008; 85(4): 1166 - 1170. [Abstract] [Full Text] [PDF]

				V. Gregoire, K. Haustermans, X. Geets, S. Roels, and M. Lonneux PET-Based Treatment Planning in Radiotherapy: A New Standard? J. Nucl. Med., January 1, 2007; 48(1_suppl): 68S - 77S. [Abstract] [Full Text] [PDF]

				K. E. Posther, L. M. McCall, D. H. Harpole Jr., C. E. Reed, J. B. Putnam Jr., V. W. Rusch, and B. A. Siegel Yield of Brain 18F-FDG PET in Evaluating Patients with Potentially Operable Non-Small Cell Lung Cancer J. Nucl. Med., October 1, 2006; 47(10): 1607 - 1611. [Abstract] [Full Text] [PDF]

				D. L. Chen and F. Dehdashti Advances in Positron Emission Tomographic Imaging of Lung Cancer Proceedings of the ATS, December 1, 2005; 2(6): 541 - 544. [Abstract] [Full Text] [PDF]

				D. B. Costa, J. A. Parker, and S. T. Schumer Modern Treatment of Lung Cancer: CASE 3. Non-Metastatic Bilateral F-18 Fluorodeoxyglucose Avid Adrenal Glands in Non-Small-Cell Lung Cancer J. Clin. Oncol., October 20, 2005; 23(30): 7740 - 7742. [Full Text] [PDF]

				G. Bastarrika, M. J. Garcia-Velloso, M. D. Lozano, U. Montes, W. Torre, N. Spiteri, A. Campo, L. Seijo, A. B. Alcaide, J. Pueyo, et al. Early Lung Cancer Detection Using Spiral Computed Tomography and Positron Emission Tomography Am. J. Respir. Crit. Care Med., June 15, 2005; 171(12): 1378 - 1383. [Abstract] [Full Text] [PDF]